Cognex Related Published Studies
Well-designed clinical trials related to Cognex (Tacrine)
Acute nicotine effects on auditory sensory memory in tacrine-treated and nontreated patients with Alzheimer's disease: an event-related potential study. [2002.05]
Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study. [2002.01]
Effects of acute nicotine administration on cognitive event-related potentials in tacrine-treated and non-treated patients with Alzheimer's disease. [2002]
Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients. [2001.01]
Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy. [1999.12]
Fluvoxamine is a potent inhibitor of tacrine metabolism in vivo. [1999.07]
A double-blind, placebo-controlled study of tacrine in Chinese patients with Alzheimer's disease. [1999.07]
Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer's disease. [1999.05]
Assessment of the value of therapeutic monitoring of tacrine in Alzheimer's disease. [1998.11]
Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer's disease. [1998.09]
Methodology, results and quality of clinical trials of tacrine in the treatment of Alzheimer's disease: a systematic review of the literature. [1998.03]
Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. [1998.03]
The pharmacological effects of ginkgo biloba, a plant extract, on the brain of dementia patients in comparison with tacrine. [1998]
Combined tacrine and estrogen replacement therapy in patients with Alzheimer's disease. [1997.09.26]
[Advantages in long-term treatment with Cognex in Alzheimer disease] [1997.08.27]
Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease. [1997.07]
Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. [1997.06]
The presence of leuko-araiosis in patients with Alzheimer's disease predicts poor tolerance to tacrine, but does not discriminate responders from non-responders. [1997.01]
Apolipoprotein E genotype and gender influence response to tacrine therapy. [1996.12.16]
The use of survival analysis techniques in evaluating the effect of long-term tacrine (Cognex) treatment on nursing home placement and mortality in patients with Alzheimer's disease. [1996.11]
[Should Alzheimer disease be treated with tacrine? Review of the literature] [1996.09.30]
An enriched-population, double-blind, placebo-controlled, crossover study of tacrine and lecithin in Alzheimer's disease. The Tacrine 970-6 Study Group. [1996.09]
Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group. [1996.07]
The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity. [1996.06]
Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. [1996.06]
Mixed-model analysis of incomplete longitudinal data from a high-dose trial of tacrine (Cognex) in Alzheimer's patients. [1996.03]
Response to tacrine in patients with dementia of the Alzheimer's type: cerebral perfusion change is related to change in mental status. [1996.02]
Evaluation of tacrine hydrochloride (Cognex) in two parallel-group studies. [1996]
Long-term effects of tacrine on regional cerebral blood flow changes in Alzheimer's disease. [1995.09]
Tacrine treatment modifies cerebrospinal fluid neuropeptide levels in Alzheimer's disease. [1994.11]
The temporal effect of food on tacrine bioavailability. [1994.10]
Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. [1994.04.06]
A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. [1994.04.06]
Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial. [1994.04.02]
Delayed matching-to-sample performance during a double-blind trial of tacrine (THA) and lecithin in patients with Alzheimer's disease. [1993]
Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. [1992.12.01]
A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. [1992.11.11]
A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. [1992.10.29]
Tacrine in Alzheimer's disease. Time course of changes in cognitive function and practice effects. [1992.01]
Tacrine in Alzheimer's disease. [1991.04.27]
Do blood pressure and age predict response to tacrine (THA) in Alzheimer's disease? A preliminary report. [1991]
The use of tacrine (THA) and succinylcholine compared with alcuronium during laparoscopy. [1990.03]
Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Francais d'Etude de la Tetrahydroaminoacridine. [1990.02.24]
Well-designed clinical trials possibly related to Cognex (Tacrine)
Neuromodulatory neurotransmitters influence LTP-like plasticity in human cortex: a pharmaco-TMS study. [2011.08]
Pathophysiology and treatment of psychosis in Parkinson's disease: a review. [2008]
Modification of practice-dependent plasticity in human motor cortex by neuromodulators. [2006.08]
A prospective randomized double masked controlled clinical trial to determine the efficacy of multiple drop centbucridine as an ocular surface anaesthetic. [2004.10]
Cholesterol and APOE genotype interact to influence Alzheimer disease progression. [2004.05.25]
Hormone replacement therapy in postmenopausal women with Alzheimer's disease: a randomized, prospective study. [2003.02]
Centbucridine, a newer topical anaesthetic compared with lignocaine: a randomized double masked single drop instillation clinical trial. [2003.01]
Acute nicotine administration in Alzheimer's disease: an exploratory EEG study. [2000]
Key methodological features of randomized controlled trials of Alzheimer's disease therapy. Minimal clinically important difference, sample size and trial duration. [1999.11]
THA improves word priming and clonidine enhances fluency and working memory in Alzheimer's disease. [1999.04]
Threats to the validity of clinical trials employing enrichment strategies for sample selection. [1998.04]
Potential role for estrogen replacement in the treatment of Alzheimer's dementia. [1997.09.22]
Frontal dysfunction blocks the therapeutic effect of THA on attention in Alzheimer's disease. [1997.05.27]
Effect of tetrahydroaminoacridine on sleep in healthy subjects. [1996.05.01]
Pupillary response to tropicamide in patients with Alzheimer disease. [1996.03]
Cardinal features of cognitive dysfunction in Alzheimer's disease: a factor-analytic study of the Alzheimer's Disease Assessment Scale. [1996.01]
Velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled trial. The Mentane Study Group. [1996]
Double-blind placebo-controlled study of velnacrine in Alzheimer's disease. [1996]
Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group. [1995.09.11]
Therapeutic trials in Alzheimer's disease. [1995.08]
Tetrahydroaminoacridine modulates technetium-99m labelled ethylene dicysteinate retention in Alzheimer's disease measured with single photon emission computed tomography imaging. [1995.07.28]
The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. [1994.12]
Cholinergic neurotransmission, REM sleep and depression. [1994]
A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease. [1993.02]
Oral tetrahydroaminoacridine treatment of Alzheimer's disease evaluated clinically and by regional cerebral blood flow and EEG. [1993.01]
Physostigmine and tetrahydroaminoacridine treatment of Alzheimer's disease. [1993]
Tetrahydroaminoacridine (THA) in Alzheimer's disease: an assessment of attentional and mnemonic function using CANTAB. [1993]
Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB. [1993]
Alzheimer's patients should be included in phase I clinical trials to evaluate compounds for Alzheimer's disease. [1992.10]
Implications of the study population in the early evaluation of anticholinesterase inhibitors for Alzheimer's disease. [1992.09]
SPECT brain imaging in Alzheimer's disease during treatment with oral tetrahydroaminoacridine and lecithin. [1992.04]
Effects of a single dose of the acetylcholinesterase inhibitor velnacrine on recognition memory and regional cerebral blood flow in Alzheimer's disease. [1992]
Quantitative EEG during a double-blind trial of THA and lecithin in patients with Alzheimer's disease. [1991.07]
Tetrahydroaminoacridine and lecithin in the treatment of Alzheimer's disease. Effect on cognition, functioning in daily life, behavioural disturbances and burden experienced by the carers. [1991.02]
Effect of tetrahydroaminoacridine on cognition, function and behaviour in Alzheimer's disease. [1991.01.01]
Multiple dose pharmacokinetics, safety, and tolerance of velnacrine (HP 029) in healthy elderly subjects: a potential therapeutic agent for Alzheimer's disease. [1990.10]
Clinical safety, tolerance, and plasma levels of the oral anticholinesterase 1,2,3,4-tetrahydro-9-aminoacridin-1-oL-maleate (HP 029) in Alzheimer's disease: preliminary findings. [1990.06]
Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study. [1990.05.03]
The effect of food on the bioavailability of velnacrine (HP 029) in healthy elderly men: a potential Alzheimer agent. [1989.10]
Single dose safety, tolerance, and pharmacokinetics of HP 029 in healthy young men: a potential Alzheimer agent. [1989.03]
Other research related to Cognex (Tacrine)
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats. [2011.03]
Cholinergic and neuroprotective drugs for the treatment of Alzheimer and neuronal vascular diseases. II. Synthesis, biological assessment, and molecular modelling of new tacrine analogues from highly substituted 2-aminopyridine-3-carbonitriles. [2011.01.01]
Tacrine-based dual binding site acetylcholinesterase inhibitors as potential disease-modifying anti-Alzheimer drug candidates. [2010.09.06]
A new tacrine-melatonin hybrid reduces amyloid burden and behavioral deficits in a mouse model of Alzheimer's disease. [2010.05]
Differential effects of systemic and intraseptal administration of the acetylcholinesterase inhibitor tacrine on the recovery of spatial behavior in an animal model of diencephalic amnesia. [2010.03.10]
Actions of bis(7)-tacrine and tacrine on transient potassium current in rat DRG neurons and potassium current mediated by K(V)4.2 expressed in Xenopus oocyte. [2010.03.08]
Neuroprotective effects of bis(7)-tacrine against glutamate-induced retinal ganglion cells damage. [2010.03.03]
Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine. [2010.02]
Tacrine-NO donor and tacrine-ferulic acid hybrid molecules as new anti-Alzheimer agents: hepatotoxicity and influence on the cytochrome P450 system in comparison to tacrine. [2010]
Tacrine derivatives and Alzheimer's disease. [2010]
Long-lasting decreases in cocaine-reinforced behavior following treatment with the cholinesterase inhibitor tacrine in rats selectively bred for drug self-administration. [2009.11]
Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds. [2009.09.10]
Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease. [2009.05.14]
Significant delivery of tacrine into the brain using magnetic chitosan microparticles for treating Alzheimer's disease. [2009.03.15]
Effects of zonisamide on c-Fos expression under conditions of tacrine-induced tremulous jaw movements in rats: a potential mechanism underlying its anti-parkinsonian tremor effect. [2009.01]
Comparison studies of tacrine and bis7-tacrine on the suppression of scopolamine-induced behavioral changes and inhibition of acetylcholinesterase in mice. [2009]
Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. [2008.09]
Bis(7)-tacrine, a promising anti-Alzheimer's dimer, affords dose- and time-dependent neuroprotection against transient focal cerebral ischemia. [2008.07.11]
|
